#	Pagina
attuale pagina	/open-h2020/projects/196218/index.html

Opendata, web and dolomites

NEUMARQ

Neurodegenerative disease biomarkers based on high quality wireless EEG.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NEUMARQ project word cloud

Explore the words cloud of the NEUMARQ project. It provides you a very rough idea of what is the project "NEUMARQ" about.

requiring treatment invasive eeg pd full electroencephalograph outcomes synucleinopathies symptoms care patient lbd fewer 6m carer commercialise worldwide phases lewy preclinical dementia people expensive disease patients time diagnosis options quality limited parkinson evolution diagnostic diseases biomarkers suffer body enormous slowing revolutionise extremely life

Project "NEUMARQ" data sheet

The following table provides information about the project.

Coordinator	STARLAB BARCELONA SL Organization address address: AVENIDA TIBIDABO 47 BIS city: BARCELONA postcode: 8035 website: www.starlab.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.starlab.es
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-01-01 to 2015-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STARLAB BARCELONA SL STARLAB BARCELONA SL Organization address address: AVENIDA TIBIDABO 47 BIS city: BARCELONA postcode: 8035 website: www.starlab.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	50˙000.00

Map

Project objective

The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care. Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUMARQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUMARQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination